Tagged with R

Boehringer Ingelheim Russia You have been with Boehringer Ingelheim since the early days of your career in 1994. In the pharmaceutical sector, managers seem to jump from company to company quite often—but you have stayed with Boehringer Ingelheim throughout executive positions in Germany, Portugal, Ukraine, Finland, and, of course, now Russia. What has…

IMS Russia You were the former director of RMBC, which was acquired in 2008 by the IMS. How important was this acquisition in terms of positioning the IMS on the Russian market? For the IMS, in terms of strategic development, this was certainly a significant acquisition—because afterwards, the organization became the leading…

Medicover You became president of the board at Medicover in Poland only a while ago and previously your previous experience was in high-profile management but not in healthcare. Do you now feel increased pressure being involved in a business where decisions take on a more ethical dimension? From a process perspective…

Roche Products (India) Pvt. Ltd. There is no doubt that India has become a country of rising opportunities. Can you first elaborate how important India has become for the Group worldwide? India has become very important, mainly because of the rising middle class population in the country. One of the problems with India however, is…

MSD Russia You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation prior to the interview, you mentioned that there has been a bit of a transition and adjustment period. How is…

Binnopharm Binnopharm was established in 2006, with 100% of charter capital coming from holding company JSFC Sistema. What was the vision behind the creation of Binnopharm? The company was indeed established in 2006, but operations did not actually begin until 2009. JSFC Sistema is a company that often works in markets…

Nycomed Russia-CIS Nycomed is currently constructing a Greenfield plant in the Yaroslavl region, at an investment of 75-80Mn EUR. Last time we met in 2006, many foreign companies viewed local production as strategically and economically unattractive. What have been the evolutions in the market that have made construction of a Russian facility…

Biocon If we look back at the conditions under which you founded Biocon in 1978, we see a young woman with a seed capital of only Rs. 10,000 in a garage in an infrastructure deficient Bangalore. Both India and Biocon have come a long way since then. How different is the…

Boehringer Ingelheim India Pvt. Ltd. Before moving into the company’s strategy, can you give our readers an idea of what role Boehringer Ingelheim India plays within the Group’s worldwide operations? Within the Boehringer Ingelheim Group, there are the mature and emerging markets for the prescription medicines. Within this structure, India falls into the emerging markets…

Pfizer Limited India To start off, can you tell us how you have seen the pharmaceutical industry developing in India? Has the perception of India by big pharma changed over the years? First of all, if you compare the growth rates of MNCs in India over the last 5 years in the pharmaceutical…

Celgene Russia Celegene did not have a Russian affiliate office during Focus Reports’ initial report on Russia in 2006. What attracted Celgene’s relatively recent entrance into this market? We had external and internal reasons, which coincided in this case. The external reason was the launch of the reimbursement system in Russia, which…

Bioceros B.V. Bioceros was founded as a service company built on the immunology expertise of its founders. Additional cell line expertise was added when you joined in 2007. What made this combination so successful? The combination of immunology and early production technology together covers the pre-clinical development of monoclonal antibodies. This combination…